Back to Search
Start Over
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
- Source :
-
Journal of hepatology [J Hepatol] 2014 Jun; Vol. 60 (6), pp. 1118-26. Date of Electronic Publication: 2014 Feb 05. - Publication Year :
- 2014
-
Abstract
- Background & Aims: Given an appreciable risk of adverse-effects, current therapies for chronic hepatitis C virus (HCV) infection pose a dilemma to patients. We explored, via simulation modelling, patient-important benefits of attaining a sustained viral response (SVR).<br />Methods: We created the HCV Individualised Treatment-decision model (the HIT-model) to simulate, on a per patient basis, the lifetime course of HCV-related liver disease according to two distinct scenarios: (i) SVR attained, and (ii) SVR not attained. Then, for each model subject, the course of liver disease under these alternative scenarios was compared. The benefit of SVR was considered in terms of two patient-important outcomes: (1) the percent-probability that SVR confers additional life-years, and (2) the percent-probability that SVR confers additional healthy life-years, where "healthy" refers to years spent in compensated disease states (i.e., the avoidance of liver failure).<br />Results: The benefit of SVR varied strikingly. It was lowest for patients aged 60 years with initially mild fibrosis; 1.6% (95% CI: 0.8-2.7) and 2.9% (95% CI: 1.5-4.7) probability of gaining life-years and healthy life-years, respectively. Whereas it was highest for patients with initially compensated cirrhosis aged 30 years; 57.9% (95% CI: 46.0-69.0) and 67.1% (95% CI: 54.1-78.2) probability of gaining life-years and healthy life-years, respectively.<br />Conclusions: For older patients with less advanced liver fibrosis, SVR is less likely to confer benefit when measured in terms of averting liver failure and premature death. These data have important implications. Foremost, it may inform the contemporary patient dilemma of immediate treatment with existing therapies (that have poor adverse effect profiles) vs. awaiting future regimens that promise better tolerability.<br /> (Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Antiviral Agents administration & dosage
Drug Therapy, Combination
Humans
Interferon-alpha therapeutic use
Liver Cirrhosis virology
Markov Chains
Middle Aged
Models, Statistical
Prognosis
Ribavirin therapeutic use
Risk Assessment methods
Severity of Illness Index
Antiviral Agents adverse effects
Decision Support Techniques
Hepacivirus drug effects
Hepatitis C, Chronic drug therapy
Hepatitis C, Chronic mortality
Liver Cirrhosis drug therapy
Liver Cirrhosis mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1600-0641
- Volume :
- 60
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 24509410
- Full Text :
- https://doi.org/10.1016/j.jhep.2014.01.020